BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/12/2026 1:58:27 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-05-07 07:18 |
|
Peer-Review Started |
|
2026-05-07 07:18 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-22 01:53 |
|
Revised |
|
2026-07-05 14:39 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-07-16 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-16 07:37 |
|
Articles in Press |
|
2026-07-16 07:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-07 00:24 |
|
Publish the Manuscript Online |
|
2026-08-12 01:58 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Neetu Gupta, Shailley Sehgal and Niti Mittal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Niti Mittal, Associate Professor, DM, Department of Pharmacology, Postgraduate Institute of Medical Sciences, Medical Road, Null, Rohtak 124001, Haryana, India. drnitimittal@uhsr.ac.in |
| Key Words |
Concurrent chemoradiotherapy; Aprepitant; Head and neck cancer; Antiemetic regimen; Complete response; Complete protection; Rescue medication |
| Core Tip |
This is the first randomised, double-blind, placebo-controlled trial evaluating aprepitant as add-on to standard antiemetic therapy in locally advanced head and neck squamous cell carcinoma patients receiving weekly cisplatin-based concurrent chemoradiotherapy. Addition of aprepitant significantly improved acute-phase complete response (97.7% vs 81.4%), complete protection in both phases, and nausea intensity without compromising safety or tolerability, supporting consideration of neurokinin-1 receptor antagonists as part of antiemetic prophylaxis in this setting, while larger studies are needed to confirm benefits during the delayed phase. |
| Publish Date |
2026-08-12 01:58 |
| Citation |
Gupta N, Sehgal S, Mittal N. Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer. World J Clin Cases 2026; 14(23): 122960
|
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i23/122960.htm |
| DOI |
https://doi.org/10.12998/wjcc.122960 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
